A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946

⚠️

This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.

About the trial

The goal of this YH42946-101 is to evaluate the safety, Tolerability, Pharmacokinetics and anti-tumor activity of YH42946 in patients with locally advanced of metastatic solid tumors with HER2 aberration and EGFR exon 20 insertions.

Original English text from ClinicalTrials.gov

Who can (and can't) join

✓ Qualifies

  • Dobry stan ogólny (możliwość normalnego funkcjonowania bez lub z małymi ograniczeniami)
  • Przewidywana długość życia co najmniej 3 miesiące
  • Nowotwór przeszedł poprzednie standardowe leczenie lub pacjent nie może być poddawany standardowym terapiom
  • Próbka guza potwierdza mutację HER2 lub EGFR
  • Jeśli były przerzuty do mózgu - wszystkie ogniska musiały być już leczone
  • Prawidłowa funkcja szpiku kostnego, wątroby, nerek i serca
  • Prawidłowe parametry krzepnięcia krwi

Simplified criteria — AI translation

Trial details

Minimum age
18 Years
Last updated (source)
August 17, 2026
Sex
No restrictions

Therapies / drugs in trial

Locations (8)

Next Oncology Virginia

Fairfax, United States

Seoul National University Bundang Hospital

Seongnam-si, South Korea

The Catholic Univ. of Korea St. Vincent's Hospital

Suwon, South Korea

Chungbuk National University Hospital

Cheongju-si, South Korea

Seoul National University Hospital

Seoul, South Korea

Severance Hospital, Yonsei University

Seoul, South Korea

Samsung Medical Center

Seoul, South Korea

Asan Medical Center, University of Ulsan

Seoul, South Korea

Trial contact

Yuhan Corporation Clinical Operation Team 1

Contact information from ClinicalTrials.gov. Contact in English.

Share this trial

Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/18/2026.

You can help another person

We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.